-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Original title: Kang·Cai｜Jindawei DRB launches Q10 beverage Yongan Pharmaceutical's taurine capacity at full capacity
Jindawei: Global sales of coenzyme Q10 powder bar fruit-flavored beverages have been planned
Jindawei: Global sales of coenzyme Q10 powder bar fruit-flavored beverages have been plannedOn February 25, Jindawei said in response to investors’ questions that the company’s Doterbex US official website has launched the Coenzyme Q10 powder bar fruit-flavored beverage product, which is a new product launched by DRB.
On February 25, Jindawei said in response to investors’ questions that the company’s Doterbex US official website has launched the Coenzyme Q10 powder bar fruit-flavored beverage product, which is a new product launched by DRB.
Yiling Pharmaceutical was rated as the Chinese patent medicine company with the highest R&D investment
On February 25, the Pharmaceutical News Agency made statistics and released the top 100 R&D investment rankings for the first three quarters of A-share listed pharmaceutical companies in 2020 (the 2020 annual report has not yet been fully disclosed).
On February 25, the Pharmaceutical News Agency made statistics and released the top 100 R&D investment rankings for the first three quarters of A-share listed pharmaceutical companies in 2020 (the 2020 annual report has not yet been fully disclosed).
R&D capability is a key factor for pharmaceutical manufacturers to achieve sustainable development and an important manifestation of core competitiveness.
2021 Hurun Global Rich List: Zhong Suisui aspires to be the richest man in Asia
On March 2, the "2021 Shimao Hong Kong-Zhuhai-Macau Port City Hurun Global Rich List" released by the Hurun Research Institute showed that the founder of Nongfu Spring, Zhong Suisui, became the richest man in China for the first time with a fortune of 550 billion yuan, and also the number one.
On March 2, the "2021 Shimao Hong Kong-Zhuhai-Macau Port City Hurun Global Rich List" released by the Hurun Research Institute showed that the founder of Nongfu Spring, Zhong Suisui, became the richest man in China for the first time with a fortune of 550 billion yuan, and also the number one.
Yong'an Pharmaceutical: full capacity production of taurine
On February 26, Yongan Pharmaceutical stated on the interactive platform that the company's production and operations are currently normal, taurine production capacity is at full capacity, production and sales are balanced, and product prices remain stable.
On February 26, Yongan Pharmaceutical stated on the interactive platform that the company's production and operations are currently normal, taurine production capacity is at full capacity, production and sales are balanced, and product prices remain stable.
